secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2026-08-12T12:04:06+00:00
Accession:  0001213900-26-088061
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive Q2 net loss narrows to $1.7M; FDA assigns OLC facility inspection
---------------------------------------------------------------------------

- Q2 2026 net loss $1.7M ($0.06/sh) vs $6.5M loss ($0.52/sh) in Q2 2025.
- Cash, equivalents, and marketable securities $61.4M at June 30, 2026; runway into 2027.
- FDA assigned facility inspection to third-party OLC manufacturer; NDA resubmission expected after successful inspection.
- June 2026 CRL cited same manufacturing deficiencies as prior CRL; no efficacy or safety concerns.
- R&D expense $2.8M (vs $1.8M); G&A $7.4M (vs $5.2M) year-over-year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390026088061/0001213900-26-088061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390026088061/ea0301699-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-088061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer